United Therapeutics (UTHR) Tops Q3 EPS by 26c; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $549.90 +1.02%
EPS Growth %: +12.6%
Financial Fact:
Net product sales: 408.2M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +12.6%
Financial Fact:
Net product sales: 408.2M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $1.52, $0.26 better than the analyst estimate of $1.26. Revenue for the quarter came in at $242.5 million versus the consensus estimate of $227.63 million.
United Therapeutics reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
United Therapeutics reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
- Qualcomm expects $40bn in non-handset revenue by fiscal 2029
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
